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ABSTRACT
Objectives: This study aims to investigate the effect of alendronate sodium on trabecular bone structure in an osteoporotic rat model.
Materials and methods: Between May 2006 and July 2006, 60 female Wistar Albino rats aged three months were randomly allocated to three 
groups: sham operated receiving no treatment (Shm); ovariectomized-alendronate receiving 1 mg/kg/day alendronate sodium (Ovx-A), and 
ovariectomized-vehicle receiving 1 mL/kg/day physiological saline (Ovx-PS). Both Ovx groups received treatment through gastric gavage 
for 56 days.
Results: Densitometric measurements showed that bone mineral density decreased in the Ovx-PS and increased in Ovx-A groups (p<0.05). 
Biomechanical measurements showed a decrease in the breaking force in the Ovx-PS group and an increase in the Ovx-A group (p<0.05). 
Histomorphometric measurements showed that the Shm group had normal trabecular structure, while the Ovx-PS group had a less well-
formed trabecular structure with a loss in the trabecular number and thickness and a corresponding increase in the trabecular spacing 
(p<0.05). In the Ovx-A group, there was an improvement in the trabecular structure with an increase in the trabecular number and thickness 
and a loss in the trabecular space (p<0.05).
Conclusion: Our study results suggest that alendronate sodium is a valuable treatment agent for osteoporosis in postmenopausal women.
Keywords: Alendronate sodium; biomechanics; densitometry; histomorphometry; osteoporosis.
Osteoporosis is a multi-factorial systemic disease 
characterized by increased bone fragility resulting 
from deterioration of the micro-architecture of the 
bone. The condition results in increased mortality 
and morbidity, particularly in postmenopausal women 
who suffer from hip and vertebral fractures.[1-3]
Currently, the most effective agents for the 
treatment of postmenopausal osteoporosis are 
bisphosphonates which are the structural analogues 
of inorganic pyrophosphates showing a selective 
activity on bone by having potent chemical affinities 
to hydroxyapatite, the main organic component 
of the bone. The use of alendronate sodium has 
been shown to increase bone mineral density 
and decrease fractures, particularly in vertebrae 
and hip, in osteoporotic patients. Several studies 
in ovariectomized (Ovx) rats have shown that 
alendronate sodium has a clinical effect for the 
treatment and protection of postmenopausal 
osteoporosis, by increasing the bone mass and 
mechanical strength.[3]
The most commonly used agents for osteoporosis 
are alendronate and risedronate: alendronate is 
more potent and selective, compared to other 
bisphosphonates, owing to its side chain of an amino 
acid group.[4]
To date, several animal models have been used to 
study the bone loss. The Ovx rat model is the most 
common model which is accepted by the United 
States Food and Drug Administration (FDA) as the 
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most appropriate model to show postmenopausal 
bone loss.[5,6]
In the present study, we aimed to investigate the 
effect of alendronate sodium on the bone trabecular 
structure using densitometric, biochemical, and 
biomechanical analyses.
MATERIALS AND METHODS
Between May 2006 and July 2006, a total of 
60-3 month old female Wistar Albino rats were 
obtained from Çukurova University Medical Research 
Center (TIBDAM). All animals received a pelleted 
standard chow diet containing 1% calcium, 0.7% 
phosphorus, 1000 IU/kg Vitamin D3, and 300 IU/kg 
Vitamin A (Tavaş Yem Sanayi ve Ticaret AŞ, Adana, 
Turkey). The rats were housed under local vivarium 
conditions (temperature 23±2 °C, humidity 55±10%, 
12-h light-dark cycle) with access to water and chow 
diet ad libitum. Animal procedures were approved 
by the Çukurova University Ethics Committee and 
performed in compliance with the guidelines of 
Çukurova University, Medical Research Center for the 
care and handling of experimental animals.
The rats were randomly allocated to the following 
groups: sham-operated control group (Shm: n=20); 
Ovx group receiving physiological saline (Ovx-PS: 
n=20); and Ovx group receiving alendronate sodium 
(Ovx-A: n=20).
Surgery was undertaken under general anesthesia: 
20 mg/kg Xylazine HCl intraperitoneally (Rompun®, 
Bayer Türk Kimya San Ltd., İstanbul, Turkey) and 
1 mg/kg ketamin (Alfamyne®, Egevet, Izmir, Turkey). 
In all groups, the abdomen was opened and, then, 
closed with the dermis and epidermis being primarily 
sutured. Bilateral ovariectomy was performed in the 
Ovx-PS and Ovx-A groups. Following operation, 
the rats were allowed to recover for seven days. The 
Ovx-A group was given 1 mg/kg/day alendronate 
sodium (Osalen, Eczacıbaşı, İstanbul, Turkey), while 
the Ovx-PS group received 1 mL/kg/day physiological 
saline, both through gastric gavage for 56 days. All 
animals were sacrificed on Day 57 by decapitation 
following intraperitoneally 10 mg/kg Xylazine HCl.
Five animals were randomly selected from each 
group for biochemical assessment and kept in 
metabolic cages prior to sacrifice. Twenty-four hour 
urine samples were obtained to measure urinary 
creatinine and calcium levels: blood samples were 
obtained from the abdominal aorta via an heparinized 
syringe from which plasma calcium, creatinine, and 
osteocalcin levels were measured.
The femurs, tibiae, and L1 and L2 vertebrae were 
removed from each animal after sacrifice and placed 
in 10% formaldehyde solution until analyzed in the 
Hard Tissue Laboratory, Department of Dentistry of 
Cukurova University.
The maximum diameters of the proximal tibial 
condyles and of the proximal tibial shafts were 
measured using digital calipers with corrected data.
Densitometric assessment was performed on the 
tibia and L1 and L2 with two measurements being 
made on each bone. The samples were placed on a 
digital sensor: an aluminum guide was used in all 
samples to provide calibration and standardization. 
The procedure was conducted using 65 Kvp, 
7.5 mA x light source (Gendex, Oralix, Milano, Italy). 
The digital images which were obtained were converted 
into TIF format and analyzed using the Bioquant 
Osteo II software (Nashville, Tennessee USA).
Ten tibiae from each group were used for mechanical 
testing. Each sample was prepared for three-point 
bending test in a Testometric AX M500 25kN machine 
(Testometric Co. Rochdale, UK). The breaking forces 
were recorded.
Undecalcified bone preparations and bone 
histomorphometry were undertaken in the Hard Tissue 
Laboratory of Cukurova University. The femurs, tibiae, 
and vertebrae samples were placed in 10% buffered 
formalin at room temperature for at least for 24 hours 
and were primarily fixed with formaldehyde solution 
at 4 °C for 15-30 min. Dehydration was by immersion 
in increasing alcohol baths (70 to 99%). The samples 
were mixed with pure glycol methyl ether acrylate 
and an embedding material (embedding medium, 
Technovit 7200 VLC) at 1:1 ratio and were kept in 
liquid for 8 to 12 hours under vacuum.
The samples were, then, embedded in specially 
designed transparent boxes under vacuum to prevent 
formation of air bubbles. The boxes were polymerized at 
40 °C under yellow light for four hours. Once penetration 
into the tissue was complete, the embedding material was 
fully polymerized under the blue light. The hardened 
blocks were, then, removed from the transparent boxes 
and 10 µm undecalcified sections prepared using EXAKT 
sensitive cutting and erosion units (EXAKT Apparatebau 
GmbH & Co KG, Norderstedt, Germany). The resulting 
sections were stained with 1% toluidine blue.
The preparations were assessed using an Olympus 
BX50 microscope (Olympus® BX50, Tokyo, Japan). 
Digital images at 40x magnification were obtained 
from the sections using a digital camera mounted 
167The effect of alendronate sodium on trabecular bone structure in an osteoporotic rat model
on the microscope. The images were analyzed using 
the Bioquant Osteo II (Bioquant Image Analysis 
Corp., Nashville, TN, USA) bone histomorphometry 
analysis program. The following parameters were 
identified: bone volume/total tissue volume 
(BV/TV), %; mineralized volume/total tissue volume 
(MV/TV), %; osteoid volume/bone volume (OV/BV), %; 
osteoid volume/total tissue volume (OV/TV), %; bone 
surface area/bone volume (BSA/BV), %; bone surface 
area/total tissue volume (BSA/TV), %; trabecular 
thickness (TbTh), μm; trabecular number (TbN), mm; 
and intertrabecular space (TbSp), μm.
Statistical analysis
Statistical analysis was performed using the SPSS 
version 15.0 software (SPSS Inc., Chicago, IL, USA). 
Descriptive data were expressed in mean and standard 
deviation (SD) with the range of values (min-max). 
Comparisons among the groups were applied using 
one-way ANOVA for normally distributed data and 
Kruskal-Wallis test for abnormally distributed data. 
The significant results were studied using the post-
hoc Bonferroni test with the assumption of a p value 
of 0.017 for each hypothesis. A p value of <0.05 was 
considered statistically significant.
RESULTS
Significantly lower levels of plasma osteocalcin and 
plasma calcium were observed in the Ovx-PS group, 
compared to both Ovx-A and Shm groups. There was 
no significant difference in plasma creatinine levels 
among the groups. However, urine calcium levels were 
significantly higher in the Ovx-PS group, compared 
to the Ovx-A and Shm groups, while urine creatinine 
levels were significantly lower in the Shm group, 
compared to the Ovx-A group (Table 1).
The diameters of the tibial head and shaft are 
presented in Table 2. Both diameters significantly 
(p<0.05) decreased in the Ovx-PS group, compared to 
Shm and Ovx-A groups.
In addition, there are marked differences in the 
bone density of the tibial and vertebral bodies among 
the groups (Table 3). For the tibial measurement, 
the Ovx-PS group had a significantly (p<0.01) lower 
density than the Shm group, while it was significantly 
(p<0.01) higher in the Ovx-A group. Similar results 
were achieved for the vertebral body densities. There 
was no difference in the bone density between the 
tibial and vertebral bodies in the Shm and Ovx-PS 
groups, although the bone density was significantly 
(p<0.01) lower in the vertebral body, than the tibia in 
the Ovx-A group.
The results from biomechanical testing for the 
tibiae are presented in Table 4. The median breaking 
force, the maximum applied force, and the force 
applied in the upward and downward direction showed 
a significant (p<0.05) decrease in the Ovx-PS group, 
Table 1. Means and standard deviations of plasma osteocalcin, creatinine, 
and calcium and of the urine creatinine and calcium values according to 
experimental groups
 Shm Ovx-PS Ovx-A
 Mean±SD Mean±SD Mean±SD
Plasma
Osteocalcin (mg/dL) 17.4±3.1 2.2±2.6* 16.9±5.7
Creatinine (mg/dL) 0.5±0.1 0.6±0.2 0.4±0.0
Calcium (mg/dL) 9.6±0.3 7.5±0.6* 9.6±0.9
Urine
Creatinine (mg/dL) 29.5±13.3** 50.4±32.5 49.5±10.1
Calcium (mg/dL) 2.1±1.7 5.9±4.6‡ 1.1±1.0
Shm: Sham; Ovx-PS, Ovariectomized-physiological saline; Ovx-A: Ovariectomized-alendronate; * p<0.05; 
** p<0.01; ‡ p<0.01.
Table 2. Means, standard deviations, and range of diameters (mm) of the tibial head and shaft according to 
experimental groups
Diameter Shm (n=10) Ovx-PS (n=10) Ovx-A (n=10)
 Mean±SD Range Mean±SD Range Mean±SD Range
Tibial head (mm) 6.5±0.2 6.27-6.95 5.8±0.3* 5.30-6.10 6.6±0.4 6.14-7.30
Tibial shaft (mm) 4.1±0.3 3.68-4.58 3.8±0.2* 3.43-3.97 4.5±0.5 4.11-5.67
Shm: Sham; Ovx-PS: Ovariectomized-physiological saline; Ovx-A: Ovariectomized-alendronate; * p<0.05.
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compared to the Shm group. In addition, there was 
a significant (p<0.05) increase in these values in the 
Ovx-A group, compared to the Ovx-PS group.
Histological sections of the undecalcified femurs 
and vertebrae showed a normal trabecular structure 
in the Shm group (Figures 1, 2). In contrast, there 
was an apparent deterioration in the Ovx-PS group 
(Figures 3, 4); however in the Ovx-A group, the 
histological sections showed a trabecular structure 
similar to the Shm group (Figures 5, 6).
The histomorphometric measurements for groups 
are shown in Table 5 for femurs and in Table 6 
for vertebrae. For the femur, all histomorphometric 
measurements showed a significant (p<0.01) change in 
the Ovx-PS group, compared to the Shm group (Table 5). 
There was a decline in the BV/TV, MV/TV, OV/BV, 
OV/TV, BSA/TV, TbN, and TbTh and an increase in 
the MV/BV, BSA/BV, and TbSp. In contrast, in the 
Ovx-A, group there were significant (p<0.01) increases, 
compared to the Shm group, in all measurements, 
except for the BSA/BV and TbSp which both showed 
a significant (p<0.01) decline (Table 5). Accordingly, 
there were significant (p<0.01) differences in all 
histomorphometric measurements between the Ovx-
PS and Ovx-A groups (Table 5), with all values being 
increased except for the BSA/BV and TbSp.
For the vertebrae, the histomorphometric 
findings were not as consistent as for the femurs 
(Table 6). Compared to the Shm group, there were 
significant (p<0.01) differences in the Ovx-PS group 
in all measurements: BV/TV, MV/BV (p<0.05), 
Table 3. Means, standard deviations, and range of densitometric values for the tibia and vertebral body according to 
experimental groups
Variable Shm (n=20) Ovx-PS (n=20) Ovx-A (n=20)
 Mean±SD Range Mean±SD Range Mean±SD Range
Tibia (mm/Al) 87.0±6.4 75.07-98.58 67.0±4.3* 59.0-76.5 114.3±6.3† 102.43-124.00
Vertebra (mm/Al) 85.0±4.1 78.97-92.69 65.7±4.0* 57.3-71.2 100.8±3.7†,‡ 95.37-109.32
Shm: Sham; Ovx-PS: Ovariectomized-physiological saline; Ovx-A: Ovariectomized-alendronate; Al: Ölçüm alanı; * p<0.01; † p<0.01; ‡ p<0.01
Table 4. Range and median values (N) of the breaking force, maximum applied force, force applied from below and from 
above for the tibia according to experimental groups
Variables Shm (n=10) Ovx-PS (n=10) Ovx-A (n=10)
 Min-Max Median Min-Max Median Min-Max Median
Breaking force (N) 0.80-10.16 4.90 0.47-15.20 3.44* 0.75-12.05 6.282†
Maximum applied force (N) 18.64-28.93 24.24 13,15-24.36 18.48* 11.97-26.67 24.032†
Force applied from below (N) 18.64-28.93 22.66 6.44-16.64 12.22* 0.00-25.99 15.932†
Force applied from above (N) 18.64-28.93 21.56 4.25-24.36 16.08* 11.97-26.67 24.022†
Shm: Sham; Ovx-PS: Ovariectomized-physiological saline; Ovx-A: Ovariectomized-alendronate; Min: Minimum; Max: Maximum; * p<0.05; † p<0.01; N: Newton.
Figure 1. Undecalcified femoral section in Shm group: 
Toluidine blue (x40). Shm: Sham; TbTh: Trabecular thickness; TbSp: 
Intertrabecular space.
Trabecula
TbTH
TbSp
Figure 2. Undecalcified vertebral section in Shm group: 
Toluidine blue (x40). Shm: Sham; TbTh: Trabecular thickness; TbSp: 
Intertrabecular space.
Trabecula
TbTH
TbSp
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MV/TV, OV/BV, OV/TV, BSA/BV, and TbN all 
decreased (p<0.01), while the BSA/BV, TbTh, and 
TbSp increased. Unlike to the femurs, there were less 
differences between the Ovx-A and Shm groups, which 
was limited to a significant (p<0.01) decline in the TbN 
and TbSp and a significant (p<0.01) increase in the 
TbTh and BSA/BV (p<0.05). Compared to the Ovx-PS 
and Ovx-A groups, there were significant (p<0.01) 
differences in all histomorphometric measurements, 
all showing increases except for TbSp and BSA/BV in 
the Shm group (p<0.05).
DISCUSSION
Osteoporosis and related postmenopausal 
complications have an adverse impact on the quality 
of life in women. Due to increased life span and 
the use of more sophisticated diagnostic techniques. 
The high rate of bone loss in the Ovx rats has been 
shown to be preventable using similar postmenopausal 
treatment regimens as in humans[7-10] As a result, the 
Ovx rat model is recognized as the gold standard 
in studies which aim to prevent and slow down 
osteoporosis in humans. In the present study, we 
developed an osteoporotic rat model to assess the 
effects of postmenopausal osteoporosis on trabecular 
bone formation. We used alendronate sodium as 
the pharmacological agent to reduce the loss of 
bone following ovariectomy. We observed highly 
significant positive effects of alendronate sodium on 
all parameters measured including plasma and urine 
biochemistry, bone morphometry, densitometry, and 
histomorphometry.
Elevated plasma osteocalcin levels following 
ovariectomy have been reported in previous studies[7-10] 
A similar finding was observed in the present study in 
the Ovx group; however, the alendronate group showed 
no change in the plasma osteocalcin levels, compared to 
the Shm group. This finding supports the bone loss in 
the Ovx group without alendronate supplementation. 
Figure 3. Undecalcified femoral section in Ovx-PS group: 
Toluidine blue (x40). Ovx-PS: Ovariectomized-physiological saline; 
TbTh: Trabecular thickness; TbSp: Intertrabecular space.
Trabecula
TbTH
TbSp
Figure 4. Undecalcified vertebral section in Ovx-PS group: 
Toluidine blue (x40). Ovx-PS: Ovariectomized-physiological saline; 
TbTh: Trabecular thickness; TbSp: Intertrabecular space.
Trabecula
TbTH
TbSp
Figure 5. Undecalcified femoral section in Ovx-A group: 
Toluidine blue (x40). Ovx-A, ovariectomized-alendronate; TbTh: 
Trabecular thickness; TbSp: Intertrabecular space.
Trabecula
TbTH
TbSp
Figure 6. Undecalcified vertebral section in Ovx-A group: 
Toluidine blue (x40). TbTh: Trabecular thickness; TbSp: Intertrabecular 
space.
Trabecula
TbTH
TbSp
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Similar positive effects of alendronate have been also 
reported in the literature.[9-17]
In addition, plasma calcium levels decreased 
in the Ovx group, compared to the Shm and 
alendronate groups with no difference between 
the Shm and alendronate groups. Iwamoto et al.[14] 
reported decreased plasma osteocalcin and urine 
deoxypyridinoline levels with increased plasma 
calcium levels in the Ovx rats. Earlier, Azuma et 
al.16 reported that plasma calcium levels decreased 
for 2 to 3 days after administration of a single dose 
of alendronate, but returned to normal values on 
Day 4. However, it is not possible to confirm these 
findings, as the plasma calcium levels were unable 
to be assessed until 57 days after ovariectomy and 
alendronate administration in our study.
Urine calcium and creatinine levels were analyzed 
using 24-hour urine samples taken immediately prior 
to sacrifice. Accordingly, creatinine levels significantly 
increased in the Ovx group supplemented with 
alendronate. A high standard deviation for the mean 
value in the unsupplemented Ovx group ref lected 
that there was no difference, compared to the Shm 
group, despite the mean value being higher than in 
the alendronate supplemented group. Urine calcium 
was also observed to be significantly higher in the 
unsupplemented Ovx group. Contrary to Shiraishi et 
al.,[17] who reported a decline in the mean calcium/
creatinine ratio in the Ovx animals, there was a 
decrease in the alendronate supplemented group, but 
an increase in the unsupplemented group in our study. 
Previously, urinary calcium was reported to decrease 
with varying doses of bisphosphonates; however, this 
decline appears not to be dose-dependent.[16] This 
can account for the differences between this study 
and that of Shiarishi et al.[17] This loss of calcium is, 
nevertheless, important, as hypercalciuria is one of 
the most common features of postmenopausal bone 
loss with osteoporosis in 50% of patients.[18,19]
Table 5. Histomorphometric analysis data for femurs
Variable Shm group (n=20) Ovx-PS group (n=20) Ovx-A group (n=20)
 Mean±SD Range Mean±SD Range Mean±SD Range
BV/TV (%) 34.8±3.4 31.20-41.60 13.9±1.8† 11.40-17.30 43.8±7.6*,‡ 28.00-69.50
MV/BV (%) 92.0±9.0 82.40-110.00 118.0±15.5* 96.80-147.10 177.3±25.1*,‡ 122.80-254.70
MV/TV (%) 27.5±2.7 24.60-32.80 12.0±1.6† 9.80-15.00 40.1±5.7*‡ 28.80-59.80
OV/BV (%) 14.9±1.5 13.30-17.80 9.0±1.2† 7.30-11.20 23.2±3.4*,‡ 16.60-35.50
OV/TV (%) 4.0±0.4 3.60-4.80 0.9±0.1† 0.70-1.10 5.7±0.9*,‡ 4.00-9.00
BSA/BV (%) 311.8±30.6 279.30-372.90 596.1±78.5* 488.90-743.40 193.3±26.9†,§ 123.70-264.00
BSA/TV (%) 84.3±8.3 75.50-100.80 55.9±7.7† 45.80-70.00 142.4±20.1*,‡ 102.20-211.80
TbN (n) 9.4±0.9 8.40-11.20 6.1±0.8† 5.00-7.60 13.0±1.8*,‡ 9.20-19.00
TbTh (μm) 46.0±4.5 41.20-55.00 27.4±3.6† 22.50-34.10 70.8±10.0*,‡ 50.90-105.50
TbSp (μm) 171.1±16.8 153.30-204.70 543.8±71.6* 446.00-678.20 145.2±24.6†,§ 87.10-239.70
Shm: Sham; Ovx-PS: Ovariectomized-physiological saline; Ovx-A: Ovariectomized-alendronate; BV/TV: Bone volume/total tissue volume; MV/BV: Mineralized volume/bone vol-
ume; MV/TV: Mineralized volume/total tissue volume; OV/BV: Osteoid volume/bone volume; OV/TV: Osteoid volume/total tissue volume; BSA/BV: Bone surface area/bone volume; 
BSA/TV: Bone surface area/total bone volume; TbN: Trabecular number; TbTh: Trabecular thickness; TbSp: Intertrabecular space; * p<0.01; † p<0.01; ‡ p<0.01; § p<0.01.
Table 6. Histomorphometric analysis data for vertebrae
Variable Shm group (n=20) Ovx-PS group (n=20) Ovx-A group (n=20)
 Mean±SD Range Mean±SD Range Mean±SD Range
BV/TV (%) 38.5±7.2 32.00-50.20 11.3±0.7** 10.20-12.60 40.6±6.2§ 32.00-50.50
MV/BV (%) 110.6±18.2 91.70-144.00 95.9±5.7‡ 86.50-107.00 116.6±17.9§ 91.70-145.00
MV/TV (%) 32.3±6.0 26.80-42.00 9.7±0.6** 8.80-10.90 34.0±5.2§ 26.80-42.30
OV/BV (%) 22.0±3.2 18.30-28.70 7.3±0.4** 6.60-8.10 23.2±3.6§ 18.30-28.90
OV/TV (%) 6.3±0.6 5.20-8.10 0.7±0.0** 0.60-0.80 6.6±1.0§ 5.19-8.21
BSA/BV (%) 378.6±34.1 303.50-200.40 484.2±28.8* 437.00-540.30 430.2±66.0†,¶ 338.50-535.10
BSA/TV (%) 113.7±27.6 94.20-147.80 45.4±2.7** 41.00-50.60 119.7±18.4§ 94.80-148.90
TbN (n) 56.8±8.4 47.10-73.90 4.9±0.3** 4.50-5.50 9.8±1.5**,§ 7.70-12.20
TbTh (μm) 9.3±0.9 7.70-12.10 20.7±1.3* 17.20-23.00 59.8±9.2* 47.10-74.40
TbSp (μm) 130.4±22.7 100.10-180.90 441.8±26.3* 398.70-492.90 13.4±2.2**,|| 10.10-19.00
Shm: Sham; Ovx-PS: Ovariectomized-physiological saline; Ovx-A: Ovariectomized-alendronate; BV/TV: Bone volume/total tissue volume; MV/BV: Mineralized volume/bone 
volume; MV/TV: Mineralized volume/total tissue volume; OV/BV: Osteoid volume/bone volume; OV/ TV: Osteoid volume/total tissue volume; BSA/BV: Bone surface area/bone 
volume; BSA/TV: Bone surface area/total bone volume; TbN: Trabecular number; TbTh: Trabecular thickness; TbSp: Intertrabecular space; * p<0.05; ** p<0.05; † p<0.05; ‡ p<0.05; 
§ p<0.05; || p<0.05; ¶ p<0.05.
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As the name refers, bone mineral density is a 
measure of the mineral content of a bone or specific 
region of a bone and, therefore, it indicates a measure of 
strength of a bone. In the present study, the diameters 
of the tibial head and shaft were significantly reduced 
in the unsupplemented Ovx group. These regions also 
showed significantly reduced bone mineral content in 
this group, compared to the alendronate supplemented 
and Shm groups. Interestingly, the alendronate group 
had significantly increased bone density, compared to 
the Shm group, which suggests a clear indication of bone 
resorption in the Ovx group and the beneficial effects 
of alendronate administration. Similar findings have 
been also reported in the literature.[9,19-21] A reduction 
in the bone mineral density has been reported for the 
greater trochanter, shaft, and distal epiphysis of the 
femur in the Ovx rats, compared to the Shm group.[16] In 
addition, Giavaresi et al.[22] reported that, in rats treated 
with alendronate sodium following ovariectomy, there 
was a 15% increase in the bone density in the femoral 
epiphysis, compared to the control group, and a 27% 
increase, compared to the Ovx unsupplemented group. 
Significant increases in the mid-shaft and proximal 
femur have been also reported.[23] These latter authors 
also reported that alendronate sodium treatment 
increased the bone thickness, strengthening both the 
cortical and medullary regions of the femoral head.
Bone mineral density of the vertebrae in our study 
showed similar values as those for the tibia. However, 
while the densities of the tibiae and vertebrae were 
similar for the Shm and unsupplemented groups, those 
for the alendronate group were significantly different 
with the density of tibiae higher than vertebrae. These 
results, together with those of previous studies,[23-33] 
indicate that alendronate sodium treatment prevents 
loss of bone mineral density in long bones, such as 
tibia and femur in rats. Furthermore, it has been also 
shown that with alendronate sodium treatment, the 
bone mineral density in L4 and L5 shows a long-term 
increase which continues even after the treatment is 
discontinued.[25-27]
In their study on Ovx rats, Fuchs et al.23 showed that 
alendronate sodium increased the bone strength as well 
as the diameter of the femoral shaft periosteum. They 
also reported an increase in femoral shaft strength, but 
not in the stiffness, which contrasts with the increased 
hardness of the femoral shaft reported by Azuma et 
al.[16] In addition, there were positive effects on the 
L4 vertebra. It was also reported that alendronate 
sodium had no effect on the three-point bending 
test, but increased the maximal loading of femoral 
shaft, irrespective of the treatment dose.[16] In another 
study, alendronate sodium and retinol significantly 
increased maximum load and breaking force of the 
femur in treated groups, compared to the Ovx animals 
not receiving treatment.[29] The biomechanical tests 
in our study showed that the tibial breaking force, 
the maximum applied force, the forces applied from 
above and below all significantly decreased in the 
unsupplemented Ovx group, compared to the Shm 
group, but significantly increased in the alendronate 
supplemented group, compared to the Ovx group. The 
decline following ovariectomy supports the findings 
of previous findings; however the adverse effects of 
osteoporosis on bone appear to be alleviated with 
the use of alendronate, as clearly seen in the present 
and previous studies. It has been also reported that 
BV/TV, one of the histomorphometric measurements, 
is a strong predictor of the mechanical properties 
of bone.[33] As this measure showed a significant 
decrease in the Ovx group, but not in the alendronate 
group, the micro-architecture of the bone in the Ovx 
unsupplemented group supports these biomechanical 
observations.
Furthermore, a decline in the bone turnover was 
reported in the Ovx rats treated with 17β-estradiol 
with the effect being more significant in the presence 
of alendronate sodium.[9] These findings support the 
hypothesis that the changes in the bone tissue and 
its material properties are the direct results of altered 
bone turnover. In this study, significant differences 
were found in all histomorphometric measurements 
between the Shm and Ovx groups for the femur with 
the unsupplemented group, showing adverse changes 
and the alendronate group showing positive changes. 
There were also significant differences between the two 
Ovx groups. Although these changes were not observed 
for the vertebrae, the unsupplemented Ovx group 
showed adverse changes, compared to the Shm group. 
In addition, there were some differences between the 
alendronate supplement and Shm groups. For the femur, 
TbTh and TbN decreased, while the TbSp increased in 
the unsupplemented Ovx group, compared to the Shm 
group, suggesting a loss of trabecular bone followed 
by osteoporosis in the Ovx group. These findings are 
similar to those reported previously.[9,16]
In addition, the administration of alendronate 
increased trabecular bone formation and trabecular 
number and volume, which can support that 
alendronate sodium protects the micro-architecture 
of the trabecular bone in the Ovx animals. These 
findings are, again, similar to those reported in the 
distal femur by da Paz et al.[9] with 17β-estradiol 
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alendronate sodium administration in the proximal 
tibial metaphysis by Iwamoto et al.14 with alendronate 
sodium and alfacalcidol. Azuma et al.[16] also reported 
an inhibition of bone loss caused by ovariectomy with 
alendronate administration, which can be attributed 
to the strong antiresorptive effect of alendronate 
sodium.
In the present study, histomorphometric 
measurements of vertebrae showed that the thickness, 
number and volume of the trabecula all decreased 
with a corresponding increase in the TbSp in the 
unsupplemented Ovx group, compared to the Shm 
group. We also found a decline in the amount of 
trabecular bone and the development of osteoporosis. 
These findings are consistent with those reported by 
Fox et al.[10] In addition, Yao et al.[34-36] and Hara et 
al.[37] who examined L5, found that vertebral volume, 
trabecular number and trabecular and cortical bone 
thicknesses all decreased in the Ovx group, compared 
to the Ovx-A group. However, they found no significant 
differences in the vertebral bone volume or bone 
architecture in the Ovx rats receiving different doses of 
simvastatin, compared to a drug-free group and a Shm 
group.[36] Despite these findings, Hara et al.[37] showed 
that alendronate treatment in the Ovx rats improved 
the vertebral bone volume, trabecular and cortical 
thickness. In the present, we also showed an increase in 
the amount of trabecular bone with an increase in the 
TbN and trabecular volume and a decline in the TbSp. 
According to our findings and previous findings, the 
use of alendronate sodium or other bisphosphonates 
is an effective way of improving trabecular bone 
structure and protecting the biomechanical strength 
of bone in the Ovx rats.
This study was conducted with a single 
antiosteoporotic drug. The results cannot be 
generalized to all antiosteoporotic agents.
In conclusion, our study results suggest that 
alendronate sodium treatment in the Ovx rats inhibits 
osteopenia in the lumbar vertebrae, protects trabecular 
structure, strengthens the bone biomechanically, and, 
inhibits bone turnover, as evidenced by the biochemical 
markers.
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